Nephros, Inc. · NASDAQ:NEPH
Nephros — Investor Presentation (2022)
16 slides from Nephros's investor presentation, May 4, 2022
Slide 1: Nephros, Inc. (Nasdaq: NEPH) FY 2021
Nephros, Inc. (Nasdaq: NEPH) FY 2021 Andy Astor, President & CEO FY 2021 Investor Presentation / Nephros, Inc.
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this management presentation constitute “forward-looking statements.” Such statements include those regarding the efficacy and intended use of our technologies under development, the timelines and strategy for bringing such products to market, the availabi
Slide 3: Better water for life
Better water for life FY 2021 Investor Presentation / Nephros, Inc.
Slide 4: Who We Are
Who We Are We provide innovative filtration and pathogen detection solutions to healthcare and commercial markets Nephros is committed to improving the human relationship with water FY 2021 Investor Presentation / Nephros, Inc. 4
Slide 5: 2021 At A Glance
2021 At A Glance $10.4M 2021 Revenue As a Deloitte “Fast 500” biotechnology company Nasdaq: NEPH (2019 and 2020), Nephros has demonstrated consistently high revenue growth and 21% 2021 YoY Growth Market Cap:$60–70M product innovation over the 55–60% Gross Margin: 35% past five years 5-Yr Revenue CAG
Slide 6: Historical Revenue Performance
Historical Revenue Performance Net Revenue Rolling Average Net Revenue 3,500 CAGR: 35% 3,000 2,500 2,000 1,500 1,000 500 - Q1 2017 Q4 2021 FY 2021 Investor Presentation / Nephros, Inc. 6
Slide 7: Nephros Solutions — Business Segments
Nephros Solutions — Business Segments Base Business New Segment 2022 Relaunch Water Pathogen Specialty While we are best known for Detection Renal Filtration Products water filtration, we offer a Systems diverse range of technologies FY 2021 Investor Presentation / Nephros, Inc. 7
Slide 8: Water Filtration
Our Business Water Segments Filtration $2.7M Q4 Revenue Retain bacteria, Our base business, solid performance; viruses, and endotoxins 20% YoY growth in 2021 Infection control within healthcare FDA 510k-cleared for 90–180 days institutions, and water purification for science dialysis, both in clinic
Slide 9: Pathogen Detection
Pathogen Detection $0.1M Q4 Revenue Growing segment; water testing is a highly fragmented, $8 billion global market science solutions Proprietary qPCR-based assays Real-time waterborne • Waterborne pathogen that identify dozens of disease- pathogen detection for detection causing pathogens. laborato
Slide 10: Specialty Renal Products
Specialty Renal Products Second-generation HDF; limited commercial launch anticipated for 2H 2022 science solutions Supported by clinical Enables HD dialysis First-generation product is research machines to perform only FDA-cleared HDF HDF dialysis treatment machine in the U.S. Improved patient outc
Slide 11: Nephros Service
Nephros Service support • Subscription-based filtration solutions • Over 99% of orders are in-stock • Same-day shipping • 100% customer satisfaction promise • Multiple national and regional service partners • Pathogen testing services that empower customers to test quickly, accurately, and on-site P
Slide 12: Our Values
Our Values Transparency We communicate with candor Integrity We are trustworthy, honest, and fair We are relatable, authentic, and lead with Approachability our humanity We focus on continuous improvement Quality and regulatory compliance We are committed to excellence in customer Service and commun
Slide 13: Our Commitment
Our Commitment In keeping with our defined purpose “to improve the human relationship with water,” we actively seek opportunities to practice corporate citizenship and engage partners that further water quality Our Engagement Partners: Nephros employees completing our Hike4Her! FY 2021 Investor Pres
Slide 14: Takeaways
Takeaways Revenue Highlights: Steady income stream from our $10.4M 2021 Revenue 2021: >20% growth over prior year. Pre-COVID: 15 consecutive growth quarters. established and growing water Post-COVID: 4 consecutive growth quarters. filtration business Potential for long-term growth supported by our r
Slide 15: Because water matters
Because water matters ™ FY 2021 Investor Presentation / Nephros, Inc.
Slide 16: Thank you
Investor Relations Contacts: nephros.com Kirin Smith, President PCG Advisory (646) 823-8656 ksmith@pcgadvisory.com Andy Astor, CEO Nephros, Inc. (201) 345-0824 andy@nephros.com Thank you FY 2021 Investor Presentation / Nephros, Inc.